Table 4 Common (≥ 20%) JS001 treatment-related adverse events from all subjects (n = 36)
Treatment-related AE | N (%) | Grade 1 | 2 | 3 | 4 |
|---|---|---|---|---|---|
Hyperglycemia | 21 (58.33%) | 19 | 1 | 1 | 0 |
Proteinuria | 18 (50.00%) | 14 | 3 | 1 | 0 |
Rash | 16 (44.44%) | 16 | 0 | 0 | 0 |
Thyroid stimulating hormone increased | 16 (44.44%) | 15 | 1 | 3 | 0 |
Lipase increased | 14 (38.89%) | 9 | 1 | 4 | 0 |
Fever | 14 (38.89%) | 13 | 1 | 0 | 0 |
Tri-iodothyronine free decreased | 13 (36.11%) | 12 | 1 | 0 | 0 |
Sinus tachycardia | 12 (33.33%) | 12 | 0 | 0 | 0 |
Anemia | 12 (33.33%) | 6 | 3 | 3 | 0 |
Leukocyturia | 11 (30.56%) | 11 | 0 | 0 | 0 |
Pruritus | 9 (25.00%) | 9 | 0 | 0 | 0 |
Leukopenia | 9 (25.00%) | 6 | 3 | 0 | 0 |
Amylase increased | 9 (25.00%) | 7 | 1 | 1 | 0 |
Thyroid hormone increases | 9 (25.00%) | 9 | 0 | 0 | 0 |
DBIL | 9 (25.00%) | 4 | 3 | 2 | 0 |
Hematuria | 9 (25.00%) | 9 | 0 | 0 | 0 |
AST increased | 9 (25.00%) | 9 | 0 | 0 | 0 |
Thyroid stimulating hormone decreased increased | 9 (25.00%) | 9 | 0 | 0 | 0 |
Hypochloremia | 9 (25.00%) | 9 | 0 | 0 | 0 |
White blood cell count increased | 8 (22.22%) | 8 | 0 | 0 | 0 |
ALT increased AAL | 8 (22.22%) | 7 | 0 | 1 | 0 |
TBIL increased | 8 (22.22%) | 6 | 2 | 0 | 0 |
Appetite decreased | 8 (22.22%) | 8 | 0 | 0 | 0 |
Fatigue | 8 (22.22%) | 7 | 1 | 0 | 0 |